ASRC Press Releases

NAD Recommends Motherlove Herbal Company Discontinue Certain Claims for ‘More Milk Plus,’ Finds Company Can Support Limited ‘Best-Selling’ Claim

The National Advertising Division has recommended that Motherlove Herbal Company discontinue claims that the company’s “More Milk Plus” dietary supplement is an “effective herbal formula designed to quickly increase breast milk for breastfeeding mothers.” NAD determined, however, that the advertiser established a reasonable basis for the claim that More Milk Plus is “Motherlove’s best selling herbal lactation formula.”

Read More

CARU Refers Advertising for ‘Jurassic World’ to MPAA for Review

The Children’s Advertising Review Unit referred advertising for Universal Pictures’ “Jurassic World” – rated PG-13 by the Motion Picture Association of America – to the MPAA for review.

Read More

NAD Finds Abbot Nutrition Can Support Challenged claims for ‘Similac Advance with OptiGRO’

NAD has determined Abbot Nutrition can support advertising claims made for the company’s Similac Advance with OptiGRO and challenged by Mead Johnson & Co., LLC.

Read More

NAD Refers Wal-Mart’s ‘Raise in Pay’ Advertising to FTC After Retailer Declines to Participate in an Advertising Review

NAD has referred broadcast advertising from Wal-Mart Stores, Inc., to the Federal Trade Commission for review, after the company declined to participate in an NAD proceeding.

Read More

NAD Refers Advertising for ASPIRE Sport Drinks to FTC After Company Declines to Discontinue Certain Advertising

NAD has referred advertising claims made by Aspire Beverage Company for its ASPIRE Sports Drinks to the Federal Trade Commission after the company declined to discontinue certain claims for the products, including “all natural” claims.

Read More

Health Solutions Commits to Discontinue Claims for ‘PhytoZon’ Supplement Following Challenge by CRN

Healthy Solutions, LLC., has said that it will discontinue challenged advertising claims for the company’s PhytoZon dietary supplement, following an inquiry from the NAD.

Read More